Stay updated on BCD-022 vs Herceptin in HER2+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the BCD-022 vs Herceptin in HER2+ Metastatic Breast Cancer Clinical Trial page.

Latest updates to the BCD-022 vs Herceptin in HER2+ Metastatic Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedThe page revision tag was updated from `v3.5.2` to `v3.5.3`, indicating a minor backend update to the page record.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision: v3.5.2 has been added, replacing the previous Revision: v3.5.0.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedA new revision label v3.5.0 was added and the previous label v3.4.3 was removed.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check83 days agoChange DetectedThe update is a minor version change (Revision: v3.4.2) and removal of a general government funding status notice; there are no changes to study content, eligibility criteria, primary or secondary outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check90 days agoChange DetectedA site-wide notice about a lapse in government funding was added and the site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to BCD-022 vs Herceptin in HER2+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BCD-022 vs Herceptin in HER2+ Metastatic Breast Cancer Clinical Trial page.